Posted inAlzheimer's Disease Cassava Sciences Inc Clinical Trials Decisions and Verdicts Falsification of Data Regulation and Deregulation of Industry Research Securities and Commodities Violations simufilam
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.